Similar to the TCGA cohort, survival analysis of the METABRIC cohort of ER-positive/HER2-negative breast cancers showed no significant differences in OS and RFS between the high and low mutation count groups (Log Rank p 0.28 and 0.9, respectively, Figure 5 and Figure 6). This evidence concerns the gene ESR1 and breast carcinoma.